“Addition of the transient outward current antagonist quinidine (5 &mgr;mol/L) or the phosphodiesterase III inhibitors cilostazol (10 &mgr;mol/L) or milrinone (5 &mgr;mol/L) diminished the ER manifestations and prevented the hypothermia-induced phase 2 reentry and VT/VF.”